Opioid treatment for acute and chronic pain in patients with sickle cell disease

  title={Opioid treatment for acute and chronic pain in patients with sickle cell disease},
  author={C Patrick Carroll},
  journal={Neuroscience Letters},
  • C. Carroll
  • Published 1 January 2020
  • Medicine, Psychology, Biology
  • Neuroscience Letters
8 Citations
Chronic opioid use in patients with sickle cell disease.
The data from the univariate analysis suggests that, in addition to concurrent psychiatric illness, patients with more severe disease are at higher risks for chronic opioid use, and patients with higher total white cell count are particularly at risk.
Pain Experiences of Adults With Sickle Cell Disease and Hematopoietic Stem Cell Transplantation: A Qualitative Study.
Clinicians should use a patient-centered approach, integrating non-opioid approaches into pain management, particularly psychosocial support as transplant for SCD becomes increasingly available, to improve health care delivery and overall patient experiences.
Patient with Sickle Cell Disease
The goal of this chapter is to provide an overview of the disease processes that drive the clinical manifestations of pain in sickle cell disease and draw attention to the distinct elements of managing the disease.
Nursing Education for the Acute Care Nurse on Pain Mechanisms of Sickle Cell Disease.
Increased knowledge does not always translate into simulated practice change, and this could include implicit bias from exposure to patients who have high use of acute care, although the minority of patients with SCD fit this description.
Patients with Sticky Platelet Syndrome, Sickle Cell Disease and Glanzmann Syndrome May Promulgate Severe Thrombosis if Infected with Covid-19.
Whether the coagulant profiles in genetically associated diseases such as sticky platelet syndrome, sickle cell disease and Glanzmann syndrome alter the thrombotic manifestations and prognosis if these patients contract Covid-19 is reviewed.
Quand la douleur devient constitutive…
Lorsque la douleur se chronicise, l’individu qui en souffre tente laborieusement de s’en arranger avec l’identité qu’il admet comme étant sienne. Les caractéristiques qui le singularisent supportent


Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease.
Chronic pain persists in adults with sickle cell disease despite regular red cell transfusions.
  • M. Karafin, Danielle E Mullins, Joshua J Field
  • Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2019
Daily Assessment of Pain in Adults with Sickle Cell Disease
The relationship among self-reported pain, crises, and health care utilization for pain in a cohort study of patients with sickle cell disease was examined, with particular emphasis on potentially mutable, causal, nonbiological variables.
Patterns of opioid use in sickle cell disease
D doses and types of opioid medications used by adult SCD patients vary widely, and findings implicate AVN and lower vitamin D levels as factors associated with higher opioid use, suggesting an association of higher bilirubin levels and higher hemolytic rate with lower opioid use.
Pain and opioid use after reversal of sickle cell disease following HLA‐matched sibling haematopoietic stem cell transplant
The prevalence and correlates of pain requiring continued opioid treatment at 12 months after successful non-myeloablative human leucocyte antigen-matched sibling allogeneic HSCT in a cohort of SCD patients are determined.
Neurobiological mechanisms of pain in sickle cell disease.
The latest evidence from the authors' studies suggests that these pathways are important for SCD pain, and can now start to elucidate neurobiological mechanisms underlying pain in SCD, which may lead to better understanding and effective therapies.
Daily home opioid use in adults with sickle cell disease: The PiSCES project.
Pain was the overwhelming characteristic associated with use, but disease-related and psychosocial variables were also associated, and opioids were used by the majority of patients.
Pain and Opioid Use after Reversal of Sickle Cell Disease Following Hematopoietic Stem Cell Transplant
SCD patients with higher pre-HSCT pain burden (more pain admissions and higher pain intensity ratings), long-acting opioid use and certain psychological traits (anxious disposition) may be at risk for persistent pain and continued opioid use after a successful HSCT.